Pyng Medical Corp. (TSX VENTURE: PYT) recently announced that it has opened its US sales office in Kirkland, Washington to service the growing demand for Pyng's line of resuscitative care solutions in the United States. The
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
Pyng is the first company to offer an adult intraosseous infusion device, and continues to lead in resuscitation innovation with simple-to-use, and highly-effective products including FAST1 Intraosseous Infusion System, FASTx Intraosseous Infusion Device, T-POD Pelvic Stabilizer, and MatTurnequet. "We have seen significant growth in our customer base and level of interest in our resuscitation products and solutions," said Robert Di Silvio, President and CEO of the Pyng." Our customers are expanding their commitment to our life-saving devices, and with that commitment, to support their efforts, we are expanding our local resources. The
Pyng Medical Corporation has been on the leading edge of intraosseous infusion since the launch of the FAST1 Intraosseous Infusion System in 1997. As a publicly traded company, Pyng Medical Corp. (TSX-V: PYT) is uniquely positioned to command a leading market position in the resuscitative urgent care market. Building off the strength of our FAST1 Intraosseous Infusion System, we are expanding internationally, penetrating new clinical applications, and are poised to diversify with complimentary product lines.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.